{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:34:26Z","timestamp":1777055666708,"version":"3.51.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Short-term moderate doses of serotonergic and dissociative hallucinogens can be useful in the treatment of anxiety. Recently, a trend has developed for long-term intermittent \u2018microdosing\u2019 (usually one-tenth of a \u2018full\u2019 active dose), with reports of long-lasting relief from anxiety and related disorders; however, there is no scientific evidence for the efficacy of therapeutic microdosing nor to show its lasting effects. The objective of this study was to test for lasting effects on anxiety in rats after microdosing with ketamine or psilocin. Over 6 days, Wistar rats (<jats:italic toggle=\"yes\">N<\/jats:italic>=40) were administered ketamine (0.5 or 3\u2009mg\/kg), psilocin (0.05 or 0.075\u2009mg\/kg), or saline on three occasions. A 5-min elevated plus-maze test was conducted 48\u2009h after the final drug treatment (<jats:italic toggle=\"yes\">n<\/jats:italic>=8). Dependent variables were entries (frequency), spent time (%), and distance traveled (cm) in each zone, as well as total frequency of rears, stretch-attend postures, and head dips. Statistical analyses of drug effects used separate independent one-way analysis of variance and pair-wise comparisons using independent <jats:italic toggle=\"yes\">t<\/jats:italic>-tests. Statistical effects were modest or borderline and were most consistent with a mildly anxiogenic profile, which was significant at lower doses; however, this conclusion remains tentative. The lower doses of ketamine and psilocin produced comparable effects (to one another) across each variable, as did the higher doses. This pattern of effects may suggest a common (e.g. neurotransmitter\/receptor) mechanism. We conclude that microdosing with hallucinogens for therapeutic purposes might be counter-productive; however, more research is needed to confirm our findings and to establish their translational relevance to clinical \u2018psychedelic\u2019 therapy.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000394","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T18:00:14Z","timestamp":1520964014000},"page":"530-536","source":"Crossref","is-referenced-by-count":43,"title":["Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats"],"prefix":"10.1097","volume":"29","author":[{"given":"Rachel R.","family":"Horsley","sequence":"first","affiliation":[{"name":"National Institute of Mental Health CZ, Klecany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"P\u00e1len\u00ed\u010dek","sequence":"additional","affiliation":[{"name":"National Institute of Mental Health CZ, Klecany"},{"name":"3rd Medical Faculty, Charles University in Prague"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Kolin","sequence":"additional","affiliation":[{"name":"National Institute of Mental Health CZ, Klecany"},{"name":"Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Vale\u0161","sequence":"additional","affiliation":[{"name":"National Institute of Mental Health CZ, Klecany"},{"name":"Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230910","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s001010050503","article-title":"From the racemate to the eutomer: (S)-ketamine. Renaissance of a substance?","volume":"46","author":"Adams","year":"1997","journal-title":"Anaesthetist"},{"key":"R2-20230910","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res Rev"},{"key":"R3-20230910","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0014-2999(01)01340-1","article-title":"Effects of ketamine on different types of anxiety","volume":"431","author":"Babar","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R4-20230910","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacol"},{"key":"R5-20230910","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0278-5846(03)00080-0","article-title":"Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia","volume":"27","author":"Becker","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R6-20230910","year":"2017"},{"key":"R7-20230910","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dta.1376","article-title":"Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses","volume":"4","author":"Bogenschutz","year":"2012","journal-title":"Drug Test Anal"},{"key":"R8-20230910","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","article-title":"Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters","volume":"359","author":"Can","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"R9-20230910","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.jchromb.2011.07.003","article-title":"Determining the pharmacokinetics of psilocin in rat plasma using ultra-performance liquid chromatography coupled with a photodiode array detector after orally administering an extract of Gymnopilus spectabilis","volume":"879","author":"Chen","year":"2011","journal-title":"J Chroma B"},{"key":"R10-20230910","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0091-3057(94)90472-3","article-title":"Ethopharmacological analysis of rat behaviour on the elevated plus-maze","volume":"49","author":"Cruz","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"R11-20230910","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/FTD.0000000000000028","article-title":"Potential therapeutic effects of psilocybin\/psilocin are minimized while possible adverse reactions are overrated","volume":"36","author":"dos Santos","year":"2014","journal-title":"Ther Drug Monitoring"},{"key":"R12-20230910","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuroscience.2009.03.038","article-title":"Anxiolytic and antidepressant-like properties of ketamine in behavioural and neurophysiological animal models","volume":"161","author":"Engin","year":"2009","journal-title":"Neurosci"},{"key":"R16-20230910","first-page":"1","article-title":"Animal tests of anxiety","volume":"10","author":"File","year":"2000","journal-title":"Curr Protoc Neurosci"},{"key":"R18-20230910","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: contributions to understanding psychosis","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"R19-20230910","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacol"},{"key":"R20-20230910","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"R21-20230910","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02247358","article-title":"5HT drugs in animal models of anxiety","volume":"112","author":"Handley","year":"1993","journal-title":"Psychopharmacol"},{"key":"R22-20230910","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm Acta Helv"},{"key":"R62-20230910","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0731-7085(02)00278-9","article-title":"Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man","volume":"30","author":"Hasler","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"R23-20230910","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2202-7-25","article-title":"Behavioral effects of ketamine and toxic interactions with psychostimulants","volume":"7","author":"Hayase","year":"2006","journal-title":"BMC Neurosci"},{"key":"R24-20230910","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.pnpbp.2007.02.007","article-title":"Lesions of the nucleus accumbens shell can reduce activity in the elevated plus-maze","volume":"31","author":"Horsley","year":"2007","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"R28-20230910","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"R29-20230910","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/jpm.2012.0617","article-title":"Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial","volume":"16","author":"Irwin","year":"2013","journal-title":"J Palliative Med"},{"key":"R30-20230910","first-page":"19575","article-title":"Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling","volume":"106","author":"Jones","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"R31-20230910","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol Psychiatry"},{"key":"R33-20230910","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/cns.12099","article-title":"Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings)","volume":"19","author":"Mion","year":"2013","journal-title":"CNS Neurosci Ther"},{"key":"R34-20230910","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"R35-20230910","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive\u2013compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R36-20230910","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R37-20230910","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000321803","article-title":"Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics","volume":"63","author":"P\u00e1len\u00ed\u010dek","year":"2011","journal-title":"Neuropsychobiol"},{"key":"R38-20230910","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.biopsych.2013.04.027","article-title":"Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats","volume":"74","author":"Parise","year":"2013","journal-title":"Biol Psychiatry"},{"key":"R39-20230910","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biol"},{"key":"R40-20230910","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0091-3057(86)90552-6","article-title":"Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat","volume":"24","author":"Pellow","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"R41-20230910","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open: closed arm entries into an elevated plus-maze as a measure of anxiety in the rat","volume":"14","author":"Pellow","year":"1985","journal-title":"J Neurosci Methods"},{"key":"R43-20230910","first-page":"180","article-title":"The Effect of Psilocin on Memory Acquisition, Retrieval, and Consolidation in the Rat. Frontiers in","volume":"8","author":"Rambousek","year":"2014","journal-title":"Behav Neurosci"},{"key":"R45-20230910","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1371\/annotation\/e580a864-cf13-40c2-9bd9-b9687a6f0fe4","article-title":"Correction: psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"Plos One"},{"key":"R46-20230910","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0091-3057(95)00138-M","article-title":"Factor analysis of spatio-temporal and ethological measures in the murine elevated plus-maze test of anxiety","volume":"52","author":"Rodgers","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"R49-20230910","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/026988110201600404","article-title":"Opposite effects of ethanol and ketamine in the elevated plus-maze test in Wistar rats undergoing a chronic oral voluntary consumption procedure","volume":"16","author":"Silvestre","year":"2002","journal-title":"J Psychopharmacol"},{"key":"R50-20230910","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/oxfordjournals.schbul.a033326","article-title":"Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia","volume":"24","author":"Swerdlow","year":"1998","journal-title":"Schizophr Bull"},{"key":"R51-20230910","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/FTD.0b013e31828741a5","article-title":"Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities","volume":"35","author":"Stebelska","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R52-20230910","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuroscience.2012.03.052","article-title":"Anti-depressant-like effects of low ketamine dose is associated with increased hippocampal AMPA\/NMDA receptor density ratio in female Wistar-Kyoto rats","volume":"213","author":"Tizabi","year":"2012","journal-title":"Neurosci"},{"key":"R54-20230910","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin \u2013 summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"R55-20230910","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/FBP.0000000000000198","article-title":"Sex differences and serotonergic mechanisms in the behavioural effects of psilocin","volume":"27","author":"Tyl\u0161","year":"2016","journal-title":"Behav Pharmacol"},{"key":"R56-20230910","first-page":"567","article-title":"Pharmacokinetics of ketamine and xylazine in young and old Sprague-Dawley rats","volume":"52","author":"Veilleux-Lemieux","year":"2013","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"R57-20230910","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues Clin Neurosci"},{"key":"R58-20230910","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: a PET study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacol"},{"key":"R59-20230910","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3956(99)00031-X","article-title":"Effects of S-ketamine on striatal dopamine release: a [11C]raclopride PET study of a model psychosis in humans","volume":"34","author":"Vollenweider","year":"2000","journal-title":"J Psychiatr Res"},{"key":"R60-20230910","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09595239600185801","article-title":"Pharmacological properties of ketamine","volume":"15","author":"White","year":"1996","journal-title":"Drug Alcohol Rev"},{"key":"R61-20230910","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008877-201809000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:03:55Z","timestamp":1694333035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008877-201809000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000394","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}